NAMPT inhibitor sensitivity of BM cell populations in AML with -7/-7q. (A) Daporinad dose response of leukemic blast cells from the BM or PB of patients with AML, measured by multiparametric flow cytometry. Samples were incubated with daporinad for 72 hours, followed by high-throughput flow cytometry–based cell viability readout. The curves highlighted in bold show patient samples with median EC50 for AML with -7/-7q (red) and AML with diploid chromosome 7 (blue). (B) Daporinad sensitivity of cell populations in AML with -7/-7q (n = 11) compared with AML without the deletion (n = 51). (C) KPT-9274 sensitivity in AML with -7/-7q (n = 10) vs without -7/-7q (n = 40). (D) GMX1778 sensitivity -7/-7q (n = 9) vs non -7/-7q (n = 40). (E) LSN3154567 sensitivity in -7/-7q (n = 10) vs non -7/-7q (n = 40). Groups were compared using Mann-Whitney U test; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001.